Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF

JCL. Himmelreich, S. Virdone, J. Camm, K. Pieper, RE. Harskamp, A. Oto, BF. Jacobson, JPS. Sawhney, TW. Lim, H. Gibbs, S. Goto, S. Haas, KAA. Fox, P. Jansky, F. Verheugt, AK. Kakkar, GARFIELD-AF investigators

. 2024 ; 11 (2) : . [pub] 20240701

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24019861

BACKGROUND: The extent to which differences in results from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial (ROCKET) atrial fibrillation (AF)-the landmark trials for the approval of apixaban and rivaroxaban, respectively, for non-valvular AF-were influenced by differences in their protocols is debated. The potential influence of selection criteria on trial results was assessed by emulating these trials in data from the Global Anticoagulant Registry in the Field (GARFIELD)-AF registry. METHODS: Vitamin K antagonist (VKA) and non-vitamin K oral antagonist (NOAC) users from GARFIELD-AF were selected according to eligibility for the original ARISTOTLE or ROCKET AF trials. A propensity score overlap weighted Cox model was used to emulate trial randomisation between treatment groups. Adjusted HRs for stroke or systemic embolism (SE) within 2 years of enrolment were calculated for each NOAC versus VKA. RESULTS: Among patients on apixaban, rivaroxaban and VKA, 2570, 3560 and 8005 were eligible for ARISTOTLE, respectively, and 1612, 2005 and 4368, respectively, for ROCKET AF. When selecting for ARISTOTLE criteria, apixaban users had significantly lower stroke/SE risk versus VKA (HR 0.57; 95% CI 0.34 to 0.94) while no reduction was observed with rivaroxaban (HR 0.98; 95% CI 0.68 to 1.40). When selecting for ROCKET AF criteria, safety and efficacy versus VKA were similar across the NOACs. CONCLUSION: Apixaban and rivaroxaban showed similar results versus VKA in high-risk patients selected according to ROCKET AF criteria, whereas differences emerged when selecting for the more inclusive ARISTOTLE criteria. Our results highlight the importance of trial selection criteria in interpreting trial results and underline the problems faced in comparing treatments across rather than within clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019861
003      
CZ-PrNML
005      
20241024111050.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/openhrt-2024-002708 $2 doi
035    __
$a (PubMed)38955399
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Himmelreich, Jelle C L $u Department of General Practice, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands j.c.himmelreich@amsterdamumc.nl $u Thrombosis Research Institute, London, UK $u Amsterdam Public Health, Personalized Medicine, Amsterdam, Netherlands $1 https://orcid.org/0000000304301583
245    10
$a Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF / $c JCL. Himmelreich, S. Virdone, J. Camm, K. Pieper, RE. Harskamp, A. Oto, BF. Jacobson, JPS. Sawhney, TW. Lim, H. Gibbs, S. Goto, S. Haas, KAA. Fox, P. Jansky, F. Verheugt, AK. Kakkar, GARFIELD-AF investigators
520    9_
$a BACKGROUND: The extent to which differences in results from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial (ROCKET) atrial fibrillation (AF)-the landmark trials for the approval of apixaban and rivaroxaban, respectively, for non-valvular AF-were influenced by differences in their protocols is debated. The potential influence of selection criteria on trial results was assessed by emulating these trials in data from the Global Anticoagulant Registry in the Field (GARFIELD)-AF registry. METHODS: Vitamin K antagonist (VKA) and non-vitamin K oral antagonist (NOAC) users from GARFIELD-AF were selected according to eligibility for the original ARISTOTLE or ROCKET AF trials. A propensity score overlap weighted Cox model was used to emulate trial randomisation between treatment groups. Adjusted HRs for stroke or systemic embolism (SE) within 2 years of enrolment were calculated for each NOAC versus VKA. RESULTS: Among patients on apixaban, rivaroxaban and VKA, 2570, 3560 and 8005 were eligible for ARISTOTLE, respectively, and 1612, 2005 and 4368, respectively, for ROCKET AF. When selecting for ARISTOTLE criteria, apixaban users had significantly lower stroke/SE risk versus VKA (HR 0.57; 95% CI 0.34 to 0.94) while no reduction was observed with rivaroxaban (HR 0.98; 95% CI 0.68 to 1.40). When selecting for ROCKET AF criteria, safety and efficacy versus VKA were similar across the NOACs. CONCLUSION: Apixaban and rivaroxaban showed similar results versus VKA in high-risk patients selected according to ROCKET AF criteria, whereas differences emerged when selecting for the more inclusive ARISTOTLE criteria. Our results highlight the importance of trial selection criteria in interpreting trial results and underline the problems faced in comparing treatments across rather than within clinical trials.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x farmakoterapie $x komplikace $7 D001281
650    12
$a inhibitory faktoru Xa $x terapeutické užití $x aplikace a dávkování $7 D065427
650    12
$a výběr pacientů $7 D018579
650    12
$a cévní mozková příhoda $x prevence a kontrola $x etiologie $7 D020521
650    12
$a pyrazoly $x terapeutické užití $7 D011720
650    12
$a pyridony $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D011728
650    12
$a rivaroxaban $x aplikace a dávkování $x terapeutické užití $7 D000069552
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a registrace $7 D012042
650    _2
$a aplikace orální $7 D000284
650    _2
$a rizikové faktory $7 D012307
650    _2
$a randomizované kontrolované studie jako téma $x metody $7 D016032
650    _2
$a hodnocení rizik $x metody $7 D018570
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a vitamin K $x antagonisté a inhibitory $7 D014812
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Virdone, Saverio $u Thrombosis Research Institute, London, UK
700    1_
$a Camm, John $u Cardiology, St George's Hospital, London, Ohio, USA
700    1_
$a Pieper, Karen $u Thrombosis Research Institute, London, UK
700    1_
$a Harskamp, Ralf E $u Department of General Practice, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands $u Amsterdam Public Health, Personalized Medicine, Amsterdam, Netherlands
700    1_
$a Oto, Ali $u Cardiology, Memorial Ankara Hospital, Ankara, Turkey
700    1_
$a Jacobson, Barry F $u University of the Witwatersrand Johannesburg, Johannesburg, South Africa
700    1_
$a Sawhney, J P S $u Sir Ganga Ram Hospital, New Delhi, India
700    1_
$a Lim, Toon Wei $u Cardiology, National University Heart Centre, Singapore
700    1_
$a Gibbs, Harry $u Medicine Alfred Hospital, Monash University, Melbourne, Victoria, Australia
700    1_
$a Goto, Shinya $u Tokai University School of Medicine Graduate School of Medicine, Isehara, Kanagawa, Japan
700    1_
$a Haas, Sylvia $u Haemostasis and Thrombosis Research Group, Institute for Experimental Oncology and Therapy Research, Formerly Technical University Munich, Munich, Germany
700    1_
$a Fox, Keith A A $u Cardiology, University of Edinburgh and Royal Infirmary, Edinburgh, UK
700    1_
$a Jansky, Petr $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Verheugt, Freek $u Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
700    1_
$a Kakkar, Ajay K $u Thrombosis Research Institute, London, UK $u Department of Surgery, University College London, London, UK
710    2_
$a GARFIELD-AF investigators
773    0_
$w MED00186378 $t Open heart $x 2053-3624 $g Roč. 11, č. 2 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38955399 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111044 $b ABA008
999    __
$a ok $b bmc $g 2202210 $s 1231834
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 11 $c 2 $e 20240701 $i 2053-3624 $m Open heart $n Open Heart $x MED00186378
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options